Notably, PPARα was expressed significantly higher in the sorafenib non-responder group compared to the responder group, as observed in the published patient cohort GSE109211 (Fig. S7g) Consistently, expression of PPARα in HCC was positively correlated with FAO-related CPT1 and CD36 expression from our immunostaining (Fig. S7h & S7i). This evidence concerns the gene CD36 and hepatocellular carcinoma.